リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「Studies on transmission dynamics of viral infectious disease by using mathematical model」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

Studies on transmission dynamics of viral infectious disease by using mathematical model

坂本, 洋平 北海道大学

2022.03.24

概要

[Background ]| Mathematical models of infectious diseases arc mathematical systems that mathematically represent and analyze the dynamics of infectious diseases in a population. Stability analysis was discussed and quantitative validity was gradually assured, and mathematical models of infectious diseases came to play an essential role in infectious disease epidemiology. When constructing and analyzing mathematical models for individual infectious diseases, it is necessary to clarify the transmission characteristics by considering factors such as the biological nature of the disease, clinical perspectives, human behavior, and individual heterogeneity Implementation of the models will be delayed, and it will lead to (he inability to spread infection if models are developed from scratch fora wide range of infectious diseases. Therefore, it is crucial to establish methodologies for each infectious disease with similar elements and adapt them quickly when an epidemic occurs. When using a mathematical model for viral infections, it is necessary to construct a model that considers factors such as "drug treatment/1 "diagnosis," "surveillance/1 "transmission route," and "vaccine" to estimate the number of potentially infected people and assess risk. This study will formulate two viral infections (Yellow fever and Cytomegalovirus (CMV)) with different characteristics and quantitatively evaluate their epidemic dynamics and risks.
[Methods] In Chapter 1, to estimate the risk of yellow fever among travelers, we analyzed both the confirmed cases in Brazil and imported cases reported abroad (Chile, Argentina, Netherlands, Switzerland, France, the United Kingdom, Romania and Germany) from May 2017 to May 2018, A statistical model was employed to capture the risk of importing yellow fever by returning international travelers from Brazil, We estimated the relative risk of importation among travelers by the extent of wealth measured by GDP per capita and the relative risk obtained by random assignment of travelers’ destination within Brazil by the relative population size. In Chapter 2, the seroepidemiological datasets (i.e. the prevalence of anti-CMV IgG antibodies) for pregnant women collected from five cord blood banks in Sapporo, Tokyo, Osaka/Kyoto, Okayama and Fukuoka from 1996 to 2009 were utilized to quantify the time-dependent transmission dynamics of CMV infection in Japan. By employing a mathematical model and using the maternal age distribution of childbirths from the Vital Statistics of Japan, we computed the seroprevalence among the pregnant Japanese women as a function of time.
[Results] In Chapter 1, travelers from wealthier fraction of countries were a = 2.3 (95% CI: 0.7, 8.6) times more likely to be infected with yellow fever compared with countries below median GDP per capita. Upper-half wealthier countries had 2.1 to 3.4 times greater risk of importation than remainders. Even among countries with lower half of GDP per capita, the risk of importation was 2.5 to 2.8 times greater than assuming that the risk of travelers’ infection within Brazil is determined by the regional population size. In Chapter 2, From a total of 22,100 samples, 16,191 were revealed to be positive, with the sample proportion positive estimated at 73.3% (95% CI: 72.7, 73.8). By linearly regressing the sample proportion by year, the seropositive fraction has decreased every year by 0.7% (p < 0.001). From 1980-2009, the median age of infection was elevated from 10.0 to 19.7 years old. A decreasing trend was observed for the force of infection, i.e., the rate at which susceptible individuals are infected, which decreased from 0.04 to 0.03 (/year) over the period from 1996 to 2009. While the total number of births has steadily declined in Japan over time, the estimated number of live births at risk of CMV infection has increased over time. Comparing the time-dependent patterns of the estimated force of infection against the different geographic locations of the co id blood banks in Japan, while a time-dependent decline was evident in Hokkaido and Fukuoka, the rate of decrease in the force of infection was slower in Tokyo.
[Discussion] In Chapter 1,we have shown that countries with wealthier GDP per capita appeared to be more often infected. It also indicates that travelers’ local destination and behavior at high risk of infection are likely to act as a key determinant of the heterogeneous risk of importing case. In addition, we found that even non-wealthy countries were at 2.5-2.8 times greater risk of importing yellow fever case as compared with a common modeling assumption that the destination-specific risk of infection is proportional to the relative population size of the destination to the entire country. Apart from the future tasks for finer estimation of the risk of infection among travelers, we believe that our study successfully quantified the relative risk of in lection by GDP per capita and also compared with the risk that rests on population-size specific assumption of travelers' destination. In Chapter 2,we indicated that the force of infection for CMV has declined over time in Japan by using blood samples from pregnant women only. Our data reveal that in 2009 in Japan, at least 0.3 million women may have been at risk of contracting a CMV infection during the perinatal period. Moreover, about 2,726 congenital CMV infections were expected to have occurred in 2009. The average age at infection has already reached the child bearing age, and it must be noted that the age at infection can be elevated even more, reaching close to 30 years old which is the ongoing mean age at child delivery.
[Conclusion] In Chapter 1, travelers from wealthier countries were at elevated risk of yellow fever, allowing us to speculate (hat travelers’ local destination and behavior at high risk of infection are likely to act as a key determinant of the heterogeneous risk of importation. It is advised to inform travelers over the ongoing geographic foci of transmission, and if it appears unavoidable to visit tourist destination that has the history of producing imported cases, travelers must be strongly advised to receive vaccination in advance. In Chapter 2, Data from the seroprevalence survey among pregnant women were analyzed as a function of time, and seropositivity among pregnant women was calculated by year. By fitting the computed probability to the observed seropositive data, we have shown that the observed decline in the proportion of CMV-positive pregnant women mirrors the steadily declining force of infection over time, Due to the elevated age at infection, pregnant women are exposed to high risk of congenital CMV infections in Japan.

この論文で使われている画像

参考文献

Almeida, L.N., Azevedo, R.S., Amaku, M., and Massad, E. (2001). Cytomegalovirus seroepidemiology in an urban community of São Paulo, Brazil. Rev. Saude. Publica. 35, 124–129.

Anderson, R. M. and May, R. M.(1982). Directly transmitted infectious diseases: Control by vaccination. Science. 215, 1053–1060.

Azevedo, R.S., and Amaku, M. (2011). Modelling immunization strategies with cytomegalovirus vaccine candidates. Epidemiol. Infect. 139, 1818–1826.

Azuma, H., Takanashi, M., Kohsaki, M., Sato, H., Ishimura, F., and Yamada, H. (2010). Cytomegalovirus seropositivity in pregnant women in Japan during 1996-2009. Journal of Japan Society of Perinatal and Neonatal Medicine 46, 1273–1279.

Bollaerts, K., Riera-Montes, M., Heininger, U., Hens, N., Souverain, A., Verstraeten, T., and Hartwig, S. (2017). A systematic review of varicella seroprevalence in European countries before universal childhood immunization: deriving incidence from seroprevalence data. Epidemiol. Infect. 145, 2666–2677.

Boven, M., Kassteele, J., Korndewal, M.J., Dorp, C.H., Kretzschmar, M., Klis, F., Melker, H.E., Vossen, A.C., and Baarle, D. (2017). Infectious reactivation of cytomegalovirus explaining age- and sex-specific patterns of seroprevalence. PLoS Comput Biol. 13: e1005719.

Central Intelligence Agency. (2017). The World Factbook. Country Comparison: GDPPer Capita (PPP). https://www.cia.gov/the-world-factbook/field/real-gdp-percapita/country-comparison (Accessed: 31 Oct 2021)

Colugnati, F.A., Staras, S.A., Dollard, S.C., and Cannnon, M.J. (2007). Incidence of cytomegalovirus infection among the general population and pregnant women in the United States. BMC Infect Dis. 7, 71.

Couto-Lima, D., Madec, Y., Bersot, M.I., Campos, S.S., Motta, M.A., Santos, F.B.D., Vazeille, M., Vasconcelos, P.F.D.C., Lourenço-de-Oliveira, R., and Failloux, A.B. (2017). Potential risk of re-emergence of urban transmission of yellow fever virus in Brazil facilitated by competent Aedes populations. Sci Rep. 7, 4848.

Dexheimer, Paploski, I.A., Souza, R.L., Tauro, L.B., Cardoso, C.W., Mugabe, V.A., Pereira, Simões, Alves, A.B., Jesus, Gomes, J., Kikuti, M., Campos, G.S., Sardi, S., et al. (2018). Epizootic outbreak of yellow fever virus and risk for human disease in Salvador, Brazil. Ann Intern Med. 168, 301–302.

Dietz, K and Heesterbeek, H. (2002). Daniel Bernoulli’s epidemiological model revisited. Math Biosci. 180, 1-21.

Dietz, K. (1988). The first epidemic model: a historical note on P.D. EN'KO. Aust. J. Stat. 30, 56-65.

Dorigatti, I., Hamlet, A., Aguas, R., Cattarino, L., Cori, A., Donnelly, C.A., Garske, T., Imai, N., and Ferguson, N.M. (2017). International risk of yellow fever spread from the ongoing outbreak in Brazil, December 2016 to May 2017. Euro Surveill. 22, 30572.

Dowd, J.B., Aiello, A.E., and Alley, D.E. (2009). Socioeconomic disparities in the seroprevalence of cytomegalovirus infection in the US population: NHANES III. Epidemiol. Infect. 137, 58–65.

Fang, F.Q., Fan, Q. S., Yang, Z.J., Peng, Y.B., Zhang, L., Mao, K.Z., Zhang, Y., and Ji, Y.H. (2009). Incidence of Cytomegalovirus Infection in Shanghai, China. Clin. Vaccine. Immunol. 16, 1700–1703.

Fernandes, G.C.V.R., Azevedo, R.S., Amaku, M., Yu, A.L.F, and Massad, E. (2009). Seroepidemiology of Toxoplasma infection in a metropolitan region of Brazil. Epidemiol. Infect. 137: 1809–1815.

Fernandes, N.C.C.A., Cunha, M.S., Guerra, J.M., Réssio, R.A., Cirqueira, C.D.S., Iglezias, S.D., de Carvalho, J., Araujo, E.L.L., Catão-Dias, J.L., and Díaz-Delgado, J. (2017). Outbreak of yellow fever among nonhuman Primates, Espirito Santo, Brazil, 2017. Emerg Infect Dis. 23, 2038–2041.

Garske, T., Van Kerkhove, M.D., Yactayo, S., Ronveaux, O., Lewis, R.F., Staples, J.E., Perea, W., and Ferguson, N.M. (2014). Yellow fever expert committee. Yellow fever in Africa: estimating the burden of disease and impact of mass vaccination from outbreak and serological data. PLoS Med. 11, e1001638.

Glasser, J., Meltzer, M. and Levin, B. (2004). Mathematical modeling and public policy: responding to health crises. Emerg Infect Dis. 10, 2050–2051.

Gossner, C.M., Haussig, J.M., de Saint, Lary, C.B., Aaslav, K.K., Schlagenhauf, P., and Sudre, B. (2018). Increased risk of yellow fever infections among unvaccinated European travellers due to ongoing outbreak in Brazil, July 2017 to March 2018. Euro Surveill. 23, 18–00106.

Griffiths, P.D., McLean, A., and Emery, V.C. (2001). Encouraging prospects for immunisation against primary cytomegalovirus infection. Vaccine 19, 1356–1362.

Hamlet, A., Jean, K., Perea, W., Yactayo, S., Biey, J., Van Kerkhove, M., Ferguson, N., and Garske, T. (2018). The seasonal influence of climate and environment on yellow fever transmission across Africa. PLoS Negl Trop Dis. 12, e0006284.

Hirota, K. (1992). Prospective study on maternal, intrauterine, and perinatal infections with cytomegalovirus in Japan during 1976-1990. J. Med. Virol. 37, 303–306.

Hogea, C., Dieussaert, I., Effelterre T.V., Guignard, A., and Mols, J. (2015). A dynamic transmission model with age-dependent infectiousness and reactivation for cytomegalovirus in the United States: Potential impact of vaccination strategies on congenital infection. Hum. Vaccine. Immunother. 11: 1788–1802.

Johansson, M.A., Vasconcelos, P.F., and Staples, J.E. (2014). The whole iceberg: estimating the incidence of yellow fever virus infection from the number of severe cases. Trans R Soc Trop Med Hyg. 108, 482–487.

Kafatos, G., Andrews, N.J., McConway, K.J., Maple, P.A.C., Brown, K., and Farrington, C.P. (2016). Is it appropriate to use fixed assay cut-offs for estimating seroprevalence? Epidemiol. Infect. 144: 887–895.

Kenneson, A.and Cannon, M.J. (2007). Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev. Med. Virol. 17, 253–276.

Kermack, W.O. and Mckendrick, A.G. (1927). Contributions to the mathematical theory of epidemics-I. Proc R Soc Lond B Biol Sci. 115, 700-721.

Lanzieri, T.M., Bialek, S.R., Ortega-Sanchez, I.R., and Gambhir, M. (2014). Modeling the potential impact of vaccination on the epidemiology of congenital cytomegalovirus infection. Vaccine. 32: 3780–3786.

Ministerio da Saude, Brazil. (2018). Monitoramento do Período Sazonal da Febre Amarela. Brasil – 2017/2018. 8 May 2018. INFORME N25. São Paulo: Ministerio da Saude; 2018. http://portalarquivos2.saude.gov.br/images/pdf/2018/maio/09/InformeFA.pdf (Accessed: 31 Oct 2021)

Ministry of Health, Labour and Welfare, Japan (MHLW). (1980-2009). Vital Statistics. Tokyo: Ministry of Health, Labour and Welfare. https://www.e-stat.go.jp/en/statsearch/files?page=1&toukei=00450011&tstat=000001028897. (Accessed: 31 Oct 2021)

Monath, T.P. (2001). Yellow fever: an update. Lancet Infect Dis. 1, 11–20.

Moreira-Soto, A., Torres, M.C., Lima, de Mendonça, M.C., Mares-Guia, M.A., Dos, Santos, Rodrigues, C.D., Fabri, A.A., Dos, Santos, C.C., Machado, Araújo, E.S., Fischer, C., Ribeiro, Nogueira, R.M., et al. (2018). Evidence for multiple sylvatic transmission cycles during the 2016-2017 yellow fever virus outbreak, Brazil. Clin Microbiol Infect. 24, 1019.

Mossong, J., Hens, N., Friederichs, V., Davidkin, I., Broman, M., Litwinska, B., Siennicka, J., Trzcinska, A., Damme, P., Beutels, P., et al. (2008). Parvovirus B19 infection in five European countries: seroepidemiology, force of infection and maternal risk of infection. Epidemiol. Infect. 136: 1059–1068.

Mossong, J., Putz, L., and Schneider, F. (2004). Seroprevalence and force of infection of varicella-zoster virus in Luxembourg. Epidemiol. Infect. 132: 1121–1127.

Nishiura, H., Tsuzuki, S., and Asai, Y. (2018). Forecasting the size and peak of cholera epidemic in Yemen, 2017. Future Microbiol. 13, 399–402.

Ogawa, H., Suzutani, T., Baba Y., Kayano, S., Nozawa, N., Ishibashi, K., Fujieda, K., Inoue, N., and Oomori, K. (2007). Etiology of severe sensorineural hearing loss in children: in- dependent impact of congenital cytomegalovirus infection and GJB2 mutations. J. Infect Dis. 195, 782–788.

Pan American Health Organization. (2018). Yellow fever. Epidemiological update on 12 January 2018. Washington D.C.: Pan American Health Organization;2018. https://www.paho.org/hq/index.php?option=comcontent&view=article&id=14043%3A12 https://www3.paho.org/hq/index.php?option=com_docman&view=download&category_slug=yellow-fever-2194&alias=43320-12-january-2018-yellow-fever-epidemiologicalupdate-320&Itemid=270&lang=en (Accessed: 31 Oct 2021)

Possas, C., Martins, R.M., Oliveira, R.L., and Homma, A. (2018). Urgent call for action:avoiding spread and re-urbanisation of yellow fever in Brazil. Mem Inst Oswaldo Cruz. 113, 1–2.

Rieder, H. (2005). Annual risk of infection with Mycobacterium tuberculosis. Eur. Respir. J. 25: 181–185.

Shearer, F.M., Longbottom, J., Browne, A.J., Pigott, D.M., Brady, O.J., Kraemer, M.U.G., Marinho, F., Yactayo, S., de Araújo, V.E.M., da Nóbrega, A.A., et al. (2018). Existing and potential infection risk zones of yellow fever worldwide: a modelling analysis. Lancet Global Health. 6, e270–278.

Shearer, F.M., Moyes, C.L., Pigott, D.M., Brady, O.J., Marinho, F., Deshpande, A., Longbottom, J., Browne, A.J., Kraemer, M.U.G., O'Reilly, K.M., et al. (2017). Global yellow fever vaccination coverage from 1970 to 2016: an adjusted retrospective analysis. Lancet Infect Dis. 17, 1209–1217.

Stagno, S., and Whitley, R.J. (1985). Herpesvirus infections of pregnancy. Part I: Cytomegalovirus and Epstein-Barr virus infections. N. Engl. J. Med. 313, 1270–1274.

Taniguchi, K., Watanabe, N., Sato, A., Jwa, S.C., Suzuki, T., Yamanobe, Y., Sago, H., and Kozuka, K. (2014). Changes in cytomegalovirus seroprevalence in pregnant Japanese women-a 10 year single center study. J. Clin. Virol. 59, 192–194.

Tsuzuki, S., Lee, H., Miura, F., Chan, Y.H., Jung, S.M., Akhmetzhanov, A.R., and Nishiura, H. (2017). Dynamics of the pneumonic plague epidemic in Madagascar, August to October 2017. Euro Surveill. 22, 17-00710.

Vyse, A.J., Hesketh, L.M., and Pebody, R.G. (2009). The burden of infection with cytomegalovirus in England and Wales: how many women are infected in pregnancy? Epidemiol. Infect. 137: 526–533.

Weigand, G. YELLOW FEVER - AMERICAS (24): GERMANY ex BRAZIL (RIO DE JANEIRO). (2018). ProMED-mail, 27 March 2018. https://www.promedmail.org/post/20180327.5714395 (Accessed: 31 Oct 2021)

Wisseman, C.L., Sweet, B.H., Kitaoka, M., and Tamiya, T. (1962). Immunological studies with group B arthropod-borne viruses. I. Broadened neutralizing antibody spectrum induced by strain 17D yellow fever vaccine in human subjects previously infected with Japanese encephalitis virus. Am J Trop Med Hyg. 11, 550–61.

World Health Organization. (2018a). Disease outbreak news on 22 January 2018. Yellow fever – Brazil. Geneva: World Health Organization. https://www.who.int/emergencies/disease-outbreak-news/item/22-january-2018-yellowfever-brazil-en (Accessed: 31 Oct 2021)

World Health Organization. (2018b). Disease outbreak news on 27 February 2018. Yellow fever – Brazil. Geneva: World Health Organization. https://www.who.int/emergencies/disease-outbreak-news/item/27-february-2018-yellowfever-brazil-en (Accessed: 31 Oct 2021)

World Health Organization. (2018c). Disease outbreak news on 9 March 2018. Yellow ever – Brazil. Geneva: World Health Organization. https://www.who.int/emergencies/disease-outbreak-news/item/09-march-2018-yellowfever-brazil-en (Accessed: 31 Oct 2021)

World Tourism Organization (UNWTO). Yearbook of Tourism Statistics dataset. (2017). Brazil. Geneva. https://www.unwto.org/global/publication/yearbook-tourism-statisticsdata-2013-2017-2019-edition (Accessed: 31 Oct 2021)

参考文献をもっと見る

全国の大学の
卒論・修論・学位論文

一発検索!

この論文の関連論文を見る